Cas:3977-79-5 1-(1-butylpiperidin-4-yl)-2-methyl-2-phenyl-3H-inden-1-ol manufacturer & supplier

Chemical Name:1-(1-butylpiperidin-4-yl)-2-methyl-2-phenyl-3H-inden-1-ol

CAS.NO:3977-79-5

Synonyms:1-(1-butyl-4-piperidyl)-2-methyl-2-phenyl-1-indanol

Molecular Formula:C₂₅H₃₃NO

Molecular Weight:363.53600

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.074

Index of Refraction:

PSA:23.47000

Exact Mass:363.25600

LogP:4.83820

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-(1-butyl-4-piperidyl)-2-methyl-2-phenyl-1-indanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-(1-butyl-4-piperidyl)-2-methyl-2-phenyl-1-indanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-(1-butyl-4-piperidyl)-2-methyl-2-phenyl-1-indanol Use and application,1-(1-butyl-4-piperidyl)-2-methyl-2-phenyl-1-indanol technical grade,usp/ep/jp grade.

Related News: Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder. (E)-1-(5-methoxycarbonyltetrazol-2-yl)hex-1-en-3-one manufacturers Moderna filed an application with the FDA for that same younger age group on June 10 but has yet to hear from the agency. States like Rhode Island have already signed off on allowing 12 to 17-year-olds to use the vaccine. 8-methoxy-3-(4-methylbenzyl)-1,2,3,4-tetrahydro-5H-chromeno[3,4-c]pyridin-5-one suppliers “The Agency also noted that no effect was seen in the two studies that included patients from EU populations, including the most recent study which involved patients who were receiving the maximum and optimal treatment for their Parkinson’s disease,” EMA said. 3-Pyridinecarboxamide, 6-methyl-N-(1-methylethyl)-N-propyl- vendor & factory He joins us at a pivotal time as our Jinkō® platform goes from strength to strength as we expand our portfolio of partnerships. Grégoire’s strategic and operational expertise will be a vital part of our future success in accelerating and de-risking clinical trials. ,Moderna filed an application with the FDA for that same younger age group on June 10 but has yet to hear from the agency. States like Rhode Island have already signed off on allowing 12 to 17-year-olds to use the vaccine.